Effectiveness of interleukin-17A inhibitors in patients with ankylosing spondylitis: A protocol for systematic review and meta-analysis
Ankylosing spondylitis is a chronic immune-mediated inflammatory arthritis. Interleukin-17A (IL-17A) inhibitors is recognized as a novel therapeutic target for ankylosing spondylitis. However, there is still a lack of high-quality research evidence regarding the issues. Therefore, we performed a pro...
Gespeichert in:
| Veröffentlicht in: | Medicine (Baltimore) 2022-12, Vol.101 (49), p.e32224-e32224 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e32224 |
|---|---|
| container_issue | 49 |
| container_start_page | e32224 |
| container_title | Medicine (Baltimore) |
| container_volume | 101 |
| creator | Yan, Mingguang Fang, Xiao Guo, Jianjun Yin, Weibing |
| description | Ankylosing spondylitis is a chronic immune-mediated inflammatory arthritis. Interleukin-17A (IL-17A) inhibitors is recognized as a novel therapeutic target for ankylosing spondylitis. However, there is still a lack of high-quality research evidence regarding the issues. Therefore, we performed a protocol for systematic review and meta-analysis to evaluate the efficacy and safety of IL-17A inhibitors in patients with ankylosing spondylitis.
This protocol will be conducted under the preferred reporting items for systematic reviews and meta-analyses protocols (PRISMA-P) guidelines. Furthermore, the study has been registered on PROSPERO (CRD42022375885). The following electronic databases will be searched regardless of language and publication status: Pubmed, MEDLINE, EMBASE, China Biomedical Database, China National Knowledge Infrastructure, VIP Database, and Wanfang Database. Cochrane "bias risk" tool is used to assess the bias risk of the quality of the included literature. Data synthesis and statistical analysis will be performed using the RevMan 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) software.
A synthesis of current evidence of IL-17A inhibitors for ankylosing spondylitis will be shown in this protocol.
This review can provide convincing evidence to help clinicians make decisions when dealing with ankylosing spondylitis. |
| doi_str_mv | 10.1097/MD.0000000000032224 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9750646</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2763332387</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4003-303bb470772b024b0672457d33123b2abd8f27596dd8548a8a1d9513418625b23</originalsourceid><addsrcrecordid>eNpdkc1u1DAUhSMEoqXwBEjISzYp9rVjJyyQRm35kVqxgbXlJE5jxokHX2dGeQJeG8OUUvDG1_I5xz76iuIlo-eMNurNzeU5_bs4AIhHxSmruCyrRorHD-aT4hniN0oZVyCeFidcSpBC8dPix9Uw2C65vZ0tIgkDcXOy0dtl6-aSqU0-j651KUTMI9mZ5OyckBxcGomZt6sP6OZbgrsw96t3yeFbsiG7GFLogidDiARXTHbKzo5Eu3f2kI09mWwypZmNX9Hh8-LJYDzaF3f7WfH1_dWXi4_l9ecPny4212UncseSU962QlGloKUgWipzoUr1nDPgLZi2rwdQuXLf15WoTW1Y31SMC1ZLqFrgZ8W7Y-5uaSfbd7lLNF7voptMXHUwTv97M7tR34a9blRFpZA54PVdQAzfF4tJTw47672ZbVhQg5Kcc-C1ylJ-lHYxIEY73D_DqP6FUN9c6v8RZterhz-89_xhlgXiKDgEn1Hh1i8HG_VojU_j77xKNVACBWBAG1pm7sD5T4qqqNo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2763332387</pqid></control><display><type>article</type><title>Effectiveness of interleukin-17A inhibitors in patients with ankylosing spondylitis: A protocol for systematic review and meta-analysis</title><source>Wolters Kluwer Open Health</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>IngentaConnect Free/Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Yan, Mingguang ; Fang, Xiao ; Guo, Jianjun ; Yin, Weibing</creator><creatorcontrib>Yan, Mingguang ; Fang, Xiao ; Guo, Jianjun ; Yin, Weibing</creatorcontrib><description>Ankylosing spondylitis is a chronic immune-mediated inflammatory arthritis. Interleukin-17A (IL-17A) inhibitors is recognized as a novel therapeutic target for ankylosing spondylitis. However, there is still a lack of high-quality research evidence regarding the issues. Therefore, we performed a protocol for systematic review and meta-analysis to evaluate the efficacy and safety of IL-17A inhibitors in patients with ankylosing spondylitis.
This protocol will be conducted under the preferred reporting items for systematic reviews and meta-analyses protocols (PRISMA-P) guidelines. Furthermore, the study has been registered on PROSPERO (CRD42022375885). The following electronic databases will be searched regardless of language and publication status: Pubmed, MEDLINE, EMBASE, China Biomedical Database, China National Knowledge Infrastructure, VIP Database, and Wanfang Database. Cochrane "bias risk" tool is used to assess the bias risk of the quality of the included literature. Data synthesis and statistical analysis will be performed using the RevMan 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) software.
A synthesis of current evidence of IL-17A inhibitors for ankylosing spondylitis will be shown in this protocol.
This review can provide convincing evidence to help clinicians make decisions when dealing with ankylosing spondylitis.</description><identifier>ISSN: 1536-5964</identifier><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000032224</identifier><identifier>PMID: 36626473</identifier><language>eng</language><publisher>United States: Lippincott Williams & Wilkins</publisher><subject>Humans ; Interleukin-17 - antagonists & inhibitors ; Meta-Analysis as Topic ; Research Design ; Spondylitis, Ankylosing - drug therapy ; Study Protocol Systematic Review ; Systematic Reviews as Topic</subject><ispartof>Medicine (Baltimore), 2022-12, Vol.101 (49), p.e32224-e32224</ispartof><rights>Lippincott Williams & Wilkins</rights><rights>Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.</rights><rights>Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4003-303bb470772b024b0672457d33123b2abd8f27596dd8548a8a1d9513418625b23</cites><orcidid>0000-0003-0904-4352</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750646/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750646/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36626473$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yan, Mingguang</creatorcontrib><creatorcontrib>Fang, Xiao</creatorcontrib><creatorcontrib>Guo, Jianjun</creatorcontrib><creatorcontrib>Yin, Weibing</creatorcontrib><title>Effectiveness of interleukin-17A inhibitors in patients with ankylosing spondylitis: A protocol for systematic review and meta-analysis</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>Ankylosing spondylitis is a chronic immune-mediated inflammatory arthritis. Interleukin-17A (IL-17A) inhibitors is recognized as a novel therapeutic target for ankylosing spondylitis. However, there is still a lack of high-quality research evidence regarding the issues. Therefore, we performed a protocol for systematic review and meta-analysis to evaluate the efficacy and safety of IL-17A inhibitors in patients with ankylosing spondylitis.
This protocol will be conducted under the preferred reporting items for systematic reviews and meta-analyses protocols (PRISMA-P) guidelines. Furthermore, the study has been registered on PROSPERO (CRD42022375885). The following electronic databases will be searched regardless of language and publication status: Pubmed, MEDLINE, EMBASE, China Biomedical Database, China National Knowledge Infrastructure, VIP Database, and Wanfang Database. Cochrane "bias risk" tool is used to assess the bias risk of the quality of the included literature. Data synthesis and statistical analysis will be performed using the RevMan 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) software.
A synthesis of current evidence of IL-17A inhibitors for ankylosing spondylitis will be shown in this protocol.
This review can provide convincing evidence to help clinicians make decisions when dealing with ankylosing spondylitis.</description><subject>Humans</subject><subject>Interleukin-17 - antagonists & inhibitors</subject><subject>Meta-Analysis as Topic</subject><subject>Research Design</subject><subject>Spondylitis, Ankylosing - drug therapy</subject><subject>Study Protocol Systematic Review</subject><subject>Systematic Reviews as Topic</subject><issn>1536-5964</issn><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkc1u1DAUhSMEoqXwBEjISzYp9rVjJyyQRm35kVqxgbXlJE5jxokHX2dGeQJeG8OUUvDG1_I5xz76iuIlo-eMNurNzeU5_bs4AIhHxSmruCyrRorHD-aT4hniN0oZVyCeFidcSpBC8dPix9Uw2C65vZ0tIgkDcXOy0dtl6-aSqU0-j651KUTMI9mZ5OyckBxcGomZt6sP6OZbgrsw96t3yeFbsiG7GFLogidDiARXTHbKzo5Eu3f2kI09mWwypZmNX9Hh8-LJYDzaF3f7WfH1_dWXi4_l9ecPny4212UncseSU962QlGloKUgWipzoUr1nDPgLZi2rwdQuXLf15WoTW1Y31SMC1ZLqFrgZ8W7Y-5uaSfbd7lLNF7voptMXHUwTv97M7tR34a9blRFpZA54PVdQAzfF4tJTw47672ZbVhQg5Kcc-C1ylJ-lHYxIEY73D_DqP6FUN9c6v8RZterhz-89_xhlgXiKDgEn1Hh1i8HG_VojU_j77xKNVACBWBAG1pm7sD5T4qqqNo</recordid><startdate>20221209</startdate><enddate>20221209</enddate><creator>Yan, Mingguang</creator><creator>Fang, Xiao</creator><creator>Guo, Jianjun</creator><creator>Yin, Weibing</creator><general>Lippincott Williams & Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0904-4352</orcidid></search><sort><creationdate>20221209</creationdate><title>Effectiveness of interleukin-17A inhibitors in patients with ankylosing spondylitis: A protocol for systematic review and meta-analysis</title><author>Yan, Mingguang ; Fang, Xiao ; Guo, Jianjun ; Yin, Weibing</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4003-303bb470772b024b0672457d33123b2abd8f27596dd8548a8a1d9513418625b23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Humans</topic><topic>Interleukin-17 - antagonists & inhibitors</topic><topic>Meta-Analysis as Topic</topic><topic>Research Design</topic><topic>Spondylitis, Ankylosing - drug therapy</topic><topic>Study Protocol Systematic Review</topic><topic>Systematic Reviews as Topic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yan, Mingguang</creatorcontrib><creatorcontrib>Fang, Xiao</creatorcontrib><creatorcontrib>Guo, Jianjun</creatorcontrib><creatorcontrib>Yin, Weibing</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yan, Mingguang</au><au>Fang, Xiao</au><au>Guo, Jianjun</au><au>Yin, Weibing</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness of interleukin-17A inhibitors in patients with ankylosing spondylitis: A protocol for systematic review and meta-analysis</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2022-12-09</date><risdate>2022</risdate><volume>101</volume><issue>49</issue><spage>e32224</spage><epage>e32224</epage><pages>e32224-e32224</pages><issn>1536-5964</issn><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>Ankylosing spondylitis is a chronic immune-mediated inflammatory arthritis. Interleukin-17A (IL-17A) inhibitors is recognized as a novel therapeutic target for ankylosing spondylitis. However, there is still a lack of high-quality research evidence regarding the issues. Therefore, we performed a protocol for systematic review and meta-analysis to evaluate the efficacy and safety of IL-17A inhibitors in patients with ankylosing spondylitis.
This protocol will be conducted under the preferred reporting items for systematic reviews and meta-analyses protocols (PRISMA-P) guidelines. Furthermore, the study has been registered on PROSPERO (CRD42022375885). The following electronic databases will be searched regardless of language and publication status: Pubmed, MEDLINE, EMBASE, China Biomedical Database, China National Knowledge Infrastructure, VIP Database, and Wanfang Database. Cochrane "bias risk" tool is used to assess the bias risk of the quality of the included literature. Data synthesis and statistical analysis will be performed using the RevMan 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) software.
A synthesis of current evidence of IL-17A inhibitors for ankylosing spondylitis will be shown in this protocol.
This review can provide convincing evidence to help clinicians make decisions when dealing with ankylosing spondylitis.</abstract><cop>United States</cop><pub>Lippincott Williams & Wilkins</pub><pmid>36626473</pmid><doi>10.1097/MD.0000000000032224</doi><orcidid>https://orcid.org/0000-0003-0904-4352</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1536-5964 |
| ispartof | Medicine (Baltimore), 2022-12, Vol.101 (49), p.e32224-e32224 |
| issn | 1536-5964 0025-7974 1536-5964 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9750646 |
| source | Wolters Kluwer Open Health; MEDLINE; DOAJ Directory of Open Access Journals; IngentaConnect Free/Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Humans Interleukin-17 - antagonists & inhibitors Meta-Analysis as Topic Research Design Spondylitis, Ankylosing - drug therapy Study Protocol Systematic Review Systematic Reviews as Topic |
| title | Effectiveness of interleukin-17A inhibitors in patients with ankylosing spondylitis: A protocol for systematic review and meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T15%3A15%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20of%20interleukin-17A%20inhibitors%20in%20patients%20with%20ankylosing%20spondylitis:%20A%20protocol%20for%20systematic%20review%20and%20meta-analysis&rft.jtitle=Medicine%20(Baltimore)&rft.au=Yan,%20Mingguang&rft.date=2022-12-09&rft.volume=101&rft.issue=49&rft.spage=e32224&rft.epage=e32224&rft.pages=e32224-e32224&rft.issn=1536-5964&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000032224&rft_dat=%3Cproquest_pubme%3E2763332387%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2763332387&rft_id=info:pmid/36626473&rfr_iscdi=true |